Results 1 to 10 of about 311,006 (351)

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma

Journal of Experimental & Clinical Cancer Research, 2022
AbstractCholangiocarcinoma (CCA) is the second most common primary liver cancer and associated with a dismal prognosis due to the lack of an efficient systemic therapy. In contrast to other cancers, new immunotherapies have demonstrated unsatisfactory results in clinical trials, underlining the importance of a deeper understanding of the special tumor ...
Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch   +8 more
doaj   +6 more sources

Tumor-Infiltrating Lymphocytes in Wilms Tumor [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
Abstract Purpose: T-lymphocytes-infiltrating tumors (TILs) are white blood cells (CD3+) found within the tumor and are thought to indicate a T-cell-mediated specific immune response. The purpose was to evaluate the presence and the subtypes of TILs in Wilms tumor (WT) specimens.
Amit K. Dinda, Sandeep Agarwala, Devendra Kumar Yadav, Vishesh Jain   +3 more
openaire   +3 more sources

Tumor-infiltrating lymphocytes in the immunotherapy era [PDF]

Cellular & Molecular Immunology, 2020
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune checkpoint inhibitor therapy in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and more recently, B cell responses within the tumor microenvironment.
S. T. Paijens, Annege Vledder, Hans W. Nijman, Marco de Bruyn   +3 more
openaire   +4 more sources

Tumor Infiltrating Lymphocytes in Ovarian Cancer [PDF]

Asian Pacific Journal of Cancer Prevention, 2015
Several improvements in ovarian cancer treatment have been achieved in recent years, both in surgery and in combination chemotherapy with targeting. However, ovarian tumors remain the women's cancers with highest mortality rates. In this scenario, a pivotal role has been endorsed to the immunological environment and to the immunological mechanisms ...
GASPARRI, MARIALUISA, Attar, R, PALAIA, INNOCENZA, PERNIOLA, GIORGIA, Marchetti, C, DI DONATO, VIOLANTE, Farooqi, Aa, Papadia, A, BENEDETTI PANICI, PIERLUIGI   +8 more
openaire   +8 more sources

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma [PDF]

New England Journal of Medicine, 2022
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking ...
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen   +56 more
openaire   +10 more sources

Tumor-Infiltrating Lymphocytes in Melanoma [PDF]

Current Oncology Reports, 2012
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective treatment for patients with metastatic melanoma. With higher response rates than ipilimumab or IL-2, and longer durations of response than vemurafenib, TIL therapy carries the potential to transform current outcomes in melanoma, while also defining the way ...
Sylvia Lee, Sylvia Lee, Kim Margolin, Kim Margolin   +3 more
openaire   +3 more sources

Immune DNA signature of T-cell infiltration in breast tumor exomes. [PDF]

, 2016
Tumor infiltrating lymphocytes (TILs) have been associated with favorable prognosis in multiple tumor types. The Cancer Genome Atlas (TCGA) represents the largest collection of cancer molecular data, but lacks detailed information about the immune ...
Armisen, Ricardo, Carter, Hannah, Dow, Michelle, Gárate Calderón, Valentina, Harismendy, Olivier, Levy, Eric, Marty, Rachel, Woo, Brian   +7 more
core   +5 more sources

Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis. [PDF]

, 2014
Tumor invasion and metastases represent a complex series of molecular events that portends a poor prognosis. The contribution of inflammatory pathways mediating this process is not well understood. Nod-like receptors (NLRs) of innate immunity function as
Chin, Arnold I, Zhang, Hanwei
core   +5 more sources

The biologic importance of tumor‐infiltrating lymphocytes [PDF]

Journal of Cutaneous Pathology, 2010
Detailed pathologic analysis has delineated a close association between intratumoral CD 8+ cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the presence at tumor sites of negative immune regulatory elements, such as FoxP 3+ T cells (Tregs) and PD‐1/PD‐L1 co‐stimulatory molecules, is closely associated with inferior ...
F. Stephen Hodi, Glenn Dranoff
openaire   +2 more sources

Siah2 control of T-regulatory cells limits anti-tumor immunity. [PDF]

, 2020
Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-based cancer therapies. Here, we report that growth of BRAF-mutant melanoma cells is inhibited, up to complete rejection, in Siah2-/- mice.
Aifantis, Ioannis, Bosenberg, Marcus, Bradley, Linda M, Brown, Kevin, Dolgalev, Igor, Feng, Yongmei, Hockemeyer, Kathryn, Li, Yan, Marine, Jean-Christophe, Otero, Dennis C, Poźniak, Joanna, Rambow, Florian, Ronai, Ze'ev A, Scortegagna, Marzia, Tinoco, Roberto, Zhang, Tongwu   +15 more
core   +2 more sources